SciSparc

About

Funding history · 9 rounds · $72.7M total

Headcount over time

Q&A

What is SciSparc's primary focus as a biopharmaceutical company?

SciSparc is a clinical-stage biopharmaceutical company that focuses on developing cannabinoid-based pharmaceuticals for central nervous system disorders, including Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's disease and agitation, Autism Spectrum Disorder, epilepsy, and pain.

When did SciSparc (formerly Therapix Biosciences) go public on NASDAQ?

SciSparc went public on NASDAQ in March 2017.

What was the total amount raised by SciSparc through funding rounds?

SciSparc has raised a total of $63,756,000 through various public offerings.

What was SciSparc's most recent public offering amount and date?

SciSparc's most recent completed public offering was in August 2023, raising $1,300,000.

What was the amount of SciSparc's public offering in May 2023?

In May 2023, SciSparc completed a public offering that raised $1,729,964.

What is one of SciSparc's key product candidates?

One of SciSparc's key product candidates is SCI-110, which is being developed for the treatment of Tourette Syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation.

Has SciSparc been granted any patents recently?

In March 2024, SciSparc was granted another patent, strengthening its core technology in Canada.

What was a significant development in SciSparc's autism spectrum disorder clinical trial in March 2024?

In March 2024, SciSparc achieved a major milestone with the first patient dosed in its Autism Spectrum Disorder clinical trial.

Sectors & technology

Highlights

Tags